MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach.
Autor(es): Cho Bo-Hyun; Clark Thomas A; Messonnier Nancy E; Ortega-Sanchez Ismael R; Weintraub Eric; Messonnier Mark L.
Resumo: The study evaluates the benefits of meningococcal conjugate vaccine (MCV4) vaccination against the burden of vaccine-associated Guillain-Barré Syndrome (GBS) using simulation. An 11-year-old cohort was followed over an 8-year period in a simulation model Table 3 Figs. 1 and 2 to estimate health outcomes to assist decision makers in setting policy. Applying a 3% discount rate, MCV4 vaccination would save 2397 quality-adjusted life years (QALYs) while vaccine-attributable GBS could result in 5 QALYs lost. Based on the result, MCV4 vaccination is strongly favored despite possible vaccine-associated GBS risk.
Imprenta: Vaccine, v. 28, n. 3, p. 817-822, 2010
Identificador do objeto digital: 10.1016/j.vaccine.2009.10.050
Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Vaccine ; Guillain-Barre Syndrome - Immunology ; Guillain-Barre Syndrome - Public health
Data de publicação: 2010
